ArticleLa Radiologia medica2020
Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta-lesion attenuation difference (ALAD) on contrast-enhanced CT.
Article in La Radiologia medica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Diagnostic value of contrast-enhanced CT in clear cell renal cell carcinoma: a systematic review and meta-analysis.BMC urology · 2024Pooled it
- Discriminating papillary renal cell carcinoma from metanephric adenoma: a quantitative contrast-enhanced CT-based analysis.Abdominal radiology (New York) · 2026Article
- Peritumoral Cortex Low-Enhancement Sign on Corticomedullary Phase CT: A Distinctive Indicator of Small Renal Malignancies.Korean journal of radiology · 2025Article
- Development of modified multi-parametric CT algorithms for diagnosing clear-cell renal cell carcinoma in small solid renal masses.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Computed tomography and magnetic resonance imaging characteristics of renal cell carcinoma: Differences between subtypes and clinical evaluation.Journal of clinical imaging science · 2025Review
- Role of Renal Biopsy in the Management of Renal Cancer: Concordance between Ultrasound/CT-Guided Biopsy Results and Definitive Pathology, Adverse Events, and Complication Rate.Journal of clinical medicine · 2023Article
- Four-phase computed tomography helps differentiation of renal oncocytoma with central hypodense areas from clear cell renal cell carcinomaDiagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- Effectiveness of Radiomic ZOT Features in the Automated Discrimination of Oncocytoma from Clear Cell Renal Cancer.Journal of personalized medicine · 2023Article
- CT differentiation of the oncocytoma and renal cell carcinoma based on peripheral tumor parenchyma and central hypodense area characterisation.BMC medical imaging · 2023Article
- Radiofrequency Ablation, Cryoablation, and Microwave Ablation for the Treatment of Small Renal Masses: Efficacy and Complications.Diagnostics (Basel, Switzerland) · 2023Review
- The Role of CT Imaging in Characterization of Small Renal Masses.Diagnostics (Basel, Switzerland) · 2023Review
- Use of specific contrast-enhanced CT regions of interest to differentiate renal oncocytomas from small clear cell and chromophobe renal cell carcinomas.Diagnostic and interventional radiology (Ankara, Turkey) · 2022Article
- Percutaneous Radiofrequency Ablation (RFA) in renal cancer. How to manage challenging masses. A narrative review.Acta bio-medica : Atenei Parmensis · 2022Review
- Diffusion weighted imaging and diffusion kurtosis imaging in abdominal oncological setting: why and when.Infectious agents and cancer · 2022Review
- Dynamic contrast-enhanced (DCE) imaging: state of the art and applications in whole-body imaging.Japanese journal of radiology · 2022Review
- Large Bowel Ischemia/Infarction: How to Recognize It and Make Differential Diagnosis? A Review.Diagnostics (Basel, Switzerland) · 2021Review
- Dual energy CT in gland tumors: a comprehensive narrative review and differential diagnosis.Gland surgery · 2020Review
- A CT-Based Radiomics Approach for the Differential Diagnosis of Sarcomatoid and Clear Cell Renal Cell Carcinoma.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe investigate the use of ratio of lesion to cortex (L/C) attenuation and aorta-lesion attenuation difference (ALAD) on multiphase contrast-enhanced CT to help distinguish oncocytoma from clear cell RCC in small renal masses (diameter < 4 cm).
methodsWe retrospectively identified 76 patients that undergo CT before surgery for a suspicious small renal mass between January 2014 and December 2018 with pathological diagnosis of 21 oncocytomas (ROs), 25 clear cell RCCs, 7 chromophobe RCCs, 7 papillary RCCs, 7 multilocular cystic RCCs, 7 angiomyolipomas and 2 leiomyomas. CT attenuation values were obtained for the tumor, the normal renal cortex and the aorta, placing a circular region of interest (ROI) in the same slice by two radiologists, independently.
resultsIn the corticomedullary phase, ROs showed isodense enhancement to the renal cortex (ratio L/C 0.92 ± 0.12), while clear cell RCCs appeared hypodense to the renal cortex (ratio L/C 0.69 ± 0.20; p < 0.01) with an accuracy of 80% for diagnosing RO. In nephrographic phase, the ratio L/C attenuation was lower than the corticomedullary phase in ROs (0.78 ± 0.11) showing an early washout pattern, while the ratio L/C was similar to the corticomedullary phase in clear cell RCCs (0.69 ± 0.13; p = 0.025, with an accuracy of 65% for diagnosing RO). The ratio L/C attenuation showed considerable overlap between ROs and clear cell RCCs in the excretory phase (p = 0.27). Mean ALAD values in the nephrographic phase were 21.95 ± 16.24 for ROs and 36.96 ± 30.53 for clear cell RCCs (p = 0.049).
conclusionThe ratio L/C attenuation in corticomedullary phase may be useful to differentiate RO from clear cell RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.